Targeted drug delivery system for transplanted organs
A Bio-orthogonal Targeting System for Precision Drug Delivery to Vascular Endothelium in Transplanted Organs
This study is exploring a new way to help organ transplants work better by delivering medication directly to the transplanted organs, which could mean fewer side effects and less need for long-term medication after surgery.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10998558 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve the success of organ transplants by developing a targeted drug delivery system. It aims to reduce the need for lifelong immunosuppressive therapy, which can lead to serious health complications. By using a bio-orthogonal targeting system, the researchers plan to deliver immunosuppressive drugs directly to the vascular endothelium of transplanted organs, minimizing side effects and enhancing organ viability. The approach involves treating donor organs with a special targeting moiety during ex vivo perfusion before transplantation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals undergoing organ transplantation who require immunosuppressive therapy.
Not a fit: Patients who are not candidates for organ transplantation or those who do not require immunosuppressive therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the health outcomes of transplant patients by reducing the risks associated with immunosuppressive therapy.
How similar studies have performed: While the approach is innovative, similar strategies in targeted drug delivery have shown promise in other medical fields, suggesting potential for success in this area as well.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Pearlman Morales, Aria — Boston University (Charles River Campus)
- Study coordinator: Pearlman Morales, Aria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.